Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Mar 05, 2019 $113.10 $114.04 $113.02 $113.90 4 598 839
Mar 04, 2019 $113.39 $113.43 $113.01 $113.04 6 143 970
Mar 01, 2019 $113.37 $113.50 $113.23 $113.28 4 346 378
Feb 28, 2019 $113.40 $113.55 $112.72 $113.30 9 002 352
Feb 27, 2019 $113.45 $113.54 $113.35 $113.40 9 471 767
Feb 26, 2019 $113.50 $113.67 $113.45 $113.45 7 844 359
Feb 25, 2019 $113.84 $114.20 $113.41 $113.48 16 240 715
Feb 22, 2019 $50.58 $52.99 $50.22 $51.56 523 886
Feb 21, 2019 $50.40 $50.73 $49.06 $50.61 534 140
Feb 20, 2019 $51.64 $51.64 $49.79 $50.89 396 554
Feb 19, 2019 $51.55 $53.27 $49.51 $51.09 1 000 318
Feb 15, 2019 $50.60 $53.14 $50.00 $52.77 854 824
Feb 14, 2019 $49.20 $50.85 $48.77 $50.60 572 929
Feb 13, 2019 $49.60 $50.39 $48.75 $49.42 343 638
Feb 12, 2019 $48.47 $49.52 $48.07 $49.45 353 756
Feb 11, 2019 $47.33 $48.45 $47.04 $48.05 300 518
Feb 08, 2019 $46.47 $47.50 $45.54 $47.44 366 371
Feb 07, 2019 $47.56 $48.41 $46.42 $46.77 380 350
Feb 06, 2019 $46.66 $48.37 $46.32 $48.26 256 314
Feb 05, 2019 $48.01 $49.60 $46.20 $46.66 370 383
Feb 04, 2019 $47.85 $48.19 $46.96 $48.15 366 898
Feb 01, 2019 $47.70 $48.02 $46.38 $47.64 889 681
Jan 31, 2019 $45.93 $47.99 $45.56 $47.82 655 616
Jan 30, 2019 $43.00 $46.04 $42.89 $45.96 567 780
Jan 29, 2019 $41.52 $42.91 $40.64 $42.76 267 576
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT